| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
EXTENDED REPORT |
1 Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, The Netherlands
2 EA 3444, Department of Clinical Epidemiology and Evaluation, University Hospital Nancy, France
3 Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands
4 Department of Rheumatology, Université Réné Descartes, Hôpital Cochin, Paris, France
5 Department of Rheumatology, University Hospital Gent, Belgium.
6 Maasland Ziekenhuis Sittard, The Netherlands
7 Faculty of Health Sciences, University Maastricht, The Netherlands
8 Department of Methodology and Statistics, University of Maastricht, The Netherlands
Correspondence to:
Correspondence to:
Dr A Boonen, Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands;
aboo{at}sint.azm.nl
Objective: To assess direct costs associated with ankylosing spondylitis (AS). To determine which variables, including country, predict costs.
Methods: 216 patients with AS from the Netherlands, France, and Belgium participated in a two year observational study and filled in bimonthly economic questionnaires. Disease related healthcare resource use was measured and direct costs were calculated from a societal perspective (true cost estimates) and from a financial perspective (country-specific tariffs). Predictors of costs were assessed using Cox’s regression analysis.
Results: 209 patients provided sufficient data for cost analysis. Mean annual societal direct costs for each patient were €2640, of which 82% were direct healthcare costs. In univariate analysis costs were higher in the Netherlands than in Belgium, but this difference disappeared after adjusting for baseline differences in patients’ characteristics among countries. Longer disease duration, lower education, worse physical function, and higher disease activity were predictors of costs. Mean annual direct costs from a financial perspective were €2122, €1402, and €941 per patient in the Netherlands, France, and Belgium, respectively. For each country, costs from a financial perspective were significantly lower than costs from a societal perspective.
Conclusion: Direct costs for AS are substantial in three European countries but not significantly different after adjusting for baseline characteristics among countries. Worse physical function and higher disease activity are important determinants of costs, suggesting better disease control might reduce the costs of AS. The difference in costs from a societal and financial perspective emphasises the importance of an economic analysis.
Keywords: ankylosing spondylitis; costs; economics
Abbreviations: ANOVA, analysis of variance; AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; COI, cost of illness; CT, computed tomography; DMARD, disease modifying antirheumatic drug; HR, hazard ratio; IBD, inflammatory bowel disease; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis
Relevant Article
Ann Rheum Dis 2003 62: 741-747.
This article has been cited by other articles:
|
|
 |
|
  T. Y. Zhu, L.-S. Tam, V. W.-Y. Lee, W. W. Hwang, T. K. Li, K. K. Lee, and E. K. Li Costs and quality of life of patients with ankylosing spondylitis in Hong Kong Rheumatology, September 1, 2008; 47(9): 1422 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Ara, J. C. Packham, and K. L. Haywood The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit Rheumatology, January 1, 2008; 47(1): 68 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Botteman, J. W. Hay, M. P. Luo, A. S. Curry, R. L. Wong, and B. A. van Hout Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom Rheumatology, August 1, 2007; 46(8): 1320 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M M Verstappen, J W G Jacobs, D M van der Heijde, S. van der Linden, C M Verhoef, J W J Bijlsma, and A Boonen Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis Ann Rheum Dis, June 1, 2007; 66(6): 727 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Huscher, S Merkesdal, K Thiele, H Zeidler, M Schneider, A Zink, and for the German Collaborative Arthritis Centres Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany Ann Rheum Dis, September 1, 2006; 65(9): 1175 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Boonen, D van der Heijde, J L Severens, A Boendermaker, R Landewe, J Braun, J Brandt, J Sieper, and S. van der Linden Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis Ann Rheum Dis, February 1, 2006; 65(2): 201 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Boonen, R van den Heuvel, A van Tubergen, M Goossens, J L Severens, D van der Heijde, and S van der Linden Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis Ann Rheum Dis, March 1, 2005; 64(3): 396 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Boonen, A van Tubergen, and S. van der Linden Insurance problems among patients with ankylosing spondylitis Ann Rheum Dis, December 1, 2003; 62(12): 1242 - 1243. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
